01840nas a2200205   4500000000100000008004100001260001200042653001300054653002400067653002000091653001300111100001400124700001300138700001400151245010300165856008400268300000900352520125900361022001401620       2025                            d  c10/202510aBiofilms10aMycobacterium avium10aDrug Resistance10aPathogen1 aMcManus W1 aMulvey K1 aSchorey J00a biofilms: mechanism of production, composition, and its role in pathogenesis and drug resistance.  uhttps://www.tandfonline.com/doi/pdf/10.1080/1040841X.2025.2580269?download=true  a1-123 a<p>The genus contains over 180 species, and new species are added frequently. Among these are several obligate pathogens, namely and the species of the complex; however, the vast majority are environmental bacteria that occupy numerous habitats and are collectively referred to as nontuberculous mycobacteria (NTM). Most NTM are harmless to humans, but the ability of some species to cause infections in people has been increasingly recognized over the past several decades. subs. has emerged as one of the most common opportunistic pathogens, usually causing pulmonary infections in susceptible people following environmental exposure. 's ability to form biofilms is key to its survival in environments that place it in close proximity to susceptible populations. Their capacity to form biofilms may also be an important aspect of their pathogenesis and known antibiotic resistance. In this review, we discuss the pathogenesis of this important mycobacterial species, what we know of its ability to form biofilms and and gaps in our knowledge of these processes. We also discuss how we may leverage our understanding of molecules involved in biofilm formation and biofilm matrix composition to develop new therapeutics targeting biofilm formation.</p>
  a1549-7828